Development of specific T-cell responses to Candida and tetanus antigens in partial DiGeorge syndrome Carla M. Davis, MD, Vikas S. Kancherla, MD, Ashwini.

Slides:

Advertisements

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Advertisements

Impaired TH17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection Howard M. Rosenblatt,

Joseph A. Odhiambo, MMed, Hywel C. Williams, PhD, Tadd O

Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD

The effects of upper respiratory infection on T-cell proliferation and steroid sensitivity of asthmatics Elcio O. Vianna, MD, PhD, Jay Westcott, PhD,

Advances in food allergy in 2015

Effect of rituximab on human in vivo antibody immune responses

Impaired TH17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy

A novel mutation in CD132 causes X-CID with defective T-cell activation and impaired humoral reactivity Taco W. Kuijpers, MD, PhD, Paul A. Baars, PhD,

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Ann-Marie M. Schoos, MD, PhD, Jacob D

Atopic dermatitis: Age and race do matter!

Immunologic defects in 22q11.2 deletion syndrome

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD

Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL- 5 and IL-5 receptor levels Miguel L. Stein, MD, Joyce M. Villanueva,

Julie Wang, MD, James H. Godbold, PhD, Hugh A. Sampson, MD

Long-term immune reconstitution after matched unrelated hematopoietic stem cell transplantation for immunodeficiency Vy Hong-Diep Kim, MD, Brenda Reid,

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD

Incident asthma and Mycoplasma pneumoniae: A nationwide cohort study

Is 9 more than 2 also in allergic airway inflammation?

Outcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without preconditioning Niraj.

Advances in basic and clinical immunology in 2011

Hospitalization rates and prognosis of patients with anaphylactic shock in Denmark from 1995 through 2012 Anni Nørgaard Jeppesen, MD, Christian Fynbo.

Rising prevalence of asthma is sex-specific in a US farming population

Functional FCGR2B gene variants influence intravenous immunoglobulin response in patients with Kawasaki disease Sadeep Shrestha, PhD, Howard W. Wiener,

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Yuichi Teraki, MD, Aika Sakurai, MD, Seiichi Izaki, MD

The National Biome Initiative: An allergy perspective

Peter M. Wolfgram, MD, David B. Allen, MD

Joseph A. Odhiambo, MMed, Hywel C. Williams, PhD, Tadd O

Alvin W. L. Schadenberg, MD, Theo van den Broek, MD, Marten A

Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA

Control lymphocyte subsets: Can one country's values serve for another's? Wilson L. Mandala, PhD, Jintanat Ananworanich, MD, PhD, Tanakorn Apornpong,

Serum tryptase levels in atopic and nonatopic children

Brent E. Palmer, PhD, Douglas G. Mack, PhD, Allison K

Reply Journal of Allergy and Clinical Immunology

Possible role of TH17 cells in the pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis Yuichi Teraki, MD, Misaki Kawabe, MD, Seiichi.

Jon Genuneit, MD, MSc Journal of Allergy and Clinical Immunology

Ricardo U. Sorensen, MD, Luke A. Wall, MD

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Food allergy in patients with primary immunodeficiency diseases: Prevalence within the US Immunodeficiency Network (USIDNET) Karen S. Tuano, MD, Jordan.

What are the best outcome measurements for atopic eczema

Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted.

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Christian Hennig, MD, Christine Happle, MD, Gesine Hansen, MD

What is an “eosinophilic phenotype” of asthma?

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Autophagy: Nobel Prize 2016 and allergy and asthma research

Advances in the approach to the patient with food allergy

A single intervention for cockroach control reduces cockroach exposure and asthma morbidity in children Felicia A. Rabito, PhD, MPH, John C. Carlson,

Effect of aging on sputum inflammation and asthma control

Sputum inflammatory cells from patients with allergic rhinitis and asthma have decreased inflammasome gene expression Willie June Brickey, PhD, Neil.

Risk of oral food challenges

Benjamin Chaigne, MD, Hervé Watier, MD, PhD

Thymic output markers indicate immune dysfunction in DiGeorge syndrome

The natural history of IgE-mediated cow's milk allergy

Usa Tantibhaedhyangkul, MD, Carla M. Davis, MD, Lenora M

Advances in basic and clinical immunology in 2013

Clinical safety of Food Allergy Herbal Formula-2 (FAHF-2) and inhibitory effect on basophils from patients with food allergy: Extended phase I study

Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection Howard M. Rosenblatt,

Macrolide antibiotics and asthma treatment

Immune pathomechanism of drug hypersensitivity reactions

Asthma: The past, future, environment, and costs

Janet Chou, MD, Maxim Lutskiy, MD, PhD, Erdyni Tsitsikov, PhD, Luigi D

Bruce K. Bacot, MD, Mary E. Paul, MD, Maritza Navarro, MD, Stuart L

Advances in pediatric asthma in 2007

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Presentation transcript:

Development of specific T-cell responses to Candida and tetanus antigens in partial DiGeorge syndrome Carla M. Davis, MD, Vikas S. Kancherla, MD, Ashwini Reddy, MD, Wenyaw Chan, PhD, Hung-Wen Yeh, PhD, Lenora M. Noroski, MD, Howard Rosenblatt, MD, William T. Shearer, MD, PhD, Javier Chinen, MD, PhD Journal of Allergy and Clinical Immunology Volume 122, Issue 6, Pages 1194-1199 (December 2008) DOI: 10.1016/j.jaci.2008.06.039 Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 CD3 T-cell absolute counts at baseline presentation. Diamonds represent individual values. Lines represent values for age-matched healthy control subjects, as indicated. Journal of Allergy and Clinical Immunology 2008 122, 1194-1199DOI: (10.1016/j.jaci.2008.06.039) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Slow decrease of CD3 T-cell counts over time. All obtained values (456 points) from 93 patients with pDGS are plotted. Data points per patient range from 1 to 21. The red line represents the overall trend calculated by using the multiple mixed linear model. A, CD3 T-cell absolute counts (in cells per cubic millimeter). B, CD3 T-cell percentages (CD3 T-cell count/total lymphocyte number). Journal of Allergy and Clinical Immunology 2008 122, 1194-1199DOI: (10.1016/j.jaci.2008.06.039) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Conserved mitogen (PHA)–stimulated lymphocyte proliferation (cpm) progress over time after baseline presentation. Available results obtained from all 93 patients are presented (438 points). Points per patient range from 1 to 19. Available results obtained from all patients are presented. The red line represents overall trend, according to the multiple mixed linear model. Journal of Allergy and Clinical Immunology 2008 122, 1194-1199DOI: (10.1016/j.jaci.2008.06.039) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 Conserved mitogen (PHA)–stimulated lymphocyte proliferation (cpm) trends over time after baseline presentation in patient groups stratified by baseline CD3 lymphocyte counts (<10th percentile [dashed line], 10th-50th percentile [dotted line], and >50th percentile [solid line] of published normal values). Journal of Allergy and Clinical Immunology 2008 122, 1194-1199DOI: (10.1016/j.jaci.2008.06.039) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 5 Increasing antigen-specific stimulated lymphocyte proliferation over time. All obtained values (443 points) from 93 patients are plotted. Data points per patient range from 1 to 19. The red line represents overall trend, according to the multiple mixed linear model. A, Candida antigen–stimulated lymphocyte proliferation (cpm). B, Candida antigen–stimulated lymphocyte proliferation (SI). C, Tetanus-stimulated lymphocyte proliferation (cpm). D, Tetanus-stimulated lymphocyte proliferation (SI). Journal of Allergy and Clinical Immunology 2008 122, 1194-1199DOI: (10.1016/j.jaci.2008.06.039) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 6 Increasing antigen-specific stimulated lymphocyte proliferation (SI) trends over time after baseline presentation in patient groups stratified by baseline CD3 lymphocyte counts (<10th percentile [dotted line], 10th-50th percentile [dashed line], and >50th percentile [solid line] of published age-matched normal values). A, Candida antigen–specific lymphoproliferative response. B, Tetanus-specific lymphoproliferative response. Journal of Allergy and Clinical Immunology 2008 122, 1194-1199DOI: (10.1016/j.jaci.2008.06.039) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 7 Development of cellular immunity to Candida antigen and tetanus after 3 tetanus immunizations. A, Cumulative percentage of vaccinated patients having immunity to antigens. B, Percentage of vaccinated patients with lymphocyte proliferation to antigens (SI >3 and cpm >1000). Ideal indicates persistent immunity, transient indicates the development of antigen immune responses with subsequent loss, and incomplete indicates the lack of development of immunity. Journal of Allergy and Clinical Immunology 2008 122, 1194-1199DOI: (10.1016/j.jaci.2008.06.039) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions